Merck Chairman and CEO Robert M. Davis said, "We strictly adhere to the highest ethical and integrity standards. We firmly believe that the importance of responsible business is at the core of our company, and we will continue to demonstrate this core value, striving to achieve our goals of saving and improving lives
To determine this year's rankings, Newsweek collaborated with global research and data firm Statista to analyze the 2000 largest publicly traded companies in the United States based on revenue, evaluate each company based on 30 key performance indicators, and survey 26000 US residents.
This year, Merck also ranked first in the industry on CNBC and JUST Capital's "America's Most Just Companies" list and Barron's Weekly's "100 Most Sustainable Companies in America" list.
About Merck
The mission of Merck (known as MSD outside of the United States and Canada) is consistent: we harness the power of cutting-edge science to save and improve lives around the world. For over 130 years, we have brought hope to humanity through the development of important drugs and vaccines. We aspire to become a globally leading research intensive biopharmaceutical company - today, we stand at the forefront of research, providing innovative health solutions to promote the prevention and treatment of human and animal diseases. We cultivate a diverse and inclusive global workforce that operates responsibly every day, creating a safe, sustainable, and healthy future for all people and communities.
Forward looking statement from Merck&Co. in Rave, New Jersey, USA
This press release from Merck&Co., Ltd. (hereinafter referred to as the "Company") in Rave, New Jersey, contains "forward-looking statements" as defined by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 in the United States. These statements are based on the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If the underlying assumptions are proven to be inaccurate or risks or uncertainties become a reality, actual results may differ significantly from those stated in forward-looking statements.
Risks and uncertainties include but are not limited to general industry conditions and competition; General economic factors, including fluctuations in interest rates and currency exchange rates; The impact of US and international pharmaceutical industry regulations and healthcare legislation; Global healthcare cost control trends; Technological advancements, new products, and patents obtained by competitors; The inherent challenges of new product development include obtaining regulatory approvals; The company's ability to accurately predict future market conditions; Manufacturing difficulties or delays; Financial instability and sovereign risks in the international economy; Reliance on the effectiveness of company patents and other innovative product protection measures; And litigation risks, including patent litigation and/or regulatory actions.
The company does not assume any obligation to publicly update any forward-looking statements, whether due to new information, future events, or other reasons. Other factors that may cause the results to differ significantly from those described in the forward-looking statements can be found in the Company's annual report on Form 10-K for the year ended December 31, 2023 and other documents submitted by the Company to the Securities and Exchange Commission (SEC), which can be found on the SEC's Internet site.